SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Perrigo Company plc and Supernus Pharmaceuticals, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Perrigo, a global leader in over-the-counter health products, has seen its SG&A expenses grow by approximately 89% from 2014 to 2023. In contrast, Supernus, a specialty pharmaceutical company, experienced a staggering 364% increase in the same period.

Key Insights

Perrigo's expenses peaked in 2023, reflecting strategic investments in global expansion. Meanwhile, Supernus's rapid growth in SG&A expenses highlights its aggressive market penetration strategy. Despite the differences, both companies demonstrate the dynamic nature of the pharmaceutical industry, where strategic spending can drive growth and innovation.

Conclusion

This analysis underscores the importance of SG&A efficiency in maintaining competitive advantage and achieving long-term success.